This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

Are sodium-glucose cotransporter-2 inhibitors safe for patients with diabetes and cancer?

kidneys
Credit: Pixabay/CC0 Public Domain

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels. In clinical trials, the risk of serious adverse events with SGLT2i has been low, but the safety outcomes of SGLT2i in patients with cancer are unknown.

A new study highlights the risk of adverse events associated with SGLT2i in with diabetes who also have cancer. The research findings will be presented at ASN Kidney Week 2023, November 1–5.

For the study, investigators assessed the outcomes of 3,872 patients with diabetes and cancer who were prescribed SGLT2i and 3,189 patients who were prescribed another diabetes medication called glucagon-like peptide 1 receptor agonists (GLP-1 RA).

Compared to GLP-1 RA, SGLT2i were associated with a higher risk of diabetic ketoacidosis (a buildup of acids in the blood) and fracture but lower risks of acute kidney injury and . There were no differences in the incidence of hypovolemia (fluid loss), , and genital infection between the SGLT2i and GLP-1 RA groups.

"This is the first study to assess the safety outcomes of SGLT2i in patients with diabetes and cancer," said corresponding author Aisha Shaikh, MD, of Memorial Sloan Kettering Cancer Center. "The study findings can inform patient-physician decision-making regarding the risks of SGLT2i in these patients."

More information: Study: Safety Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Diabetes Mellitus and Cancer

Citation: Are sodium-glucose cotransporter-2 inhibitors safe for patients with diabetes and cancer? (2023, November 2) retrieved 18 June 2024 from https://medicalxpress.com/news/2023-11-sodium-glucose-cotransporter-inhibitors-safe-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Research shows the newest glucose-lowering drug could reduce the risks of renal and respiratory diseases

1 shares

Feedback to editors